Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System®. Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, …
Trending at Lumira Ventures
Cardiac Dimensions Hires Gretchen Gary as VP of Global Therapy Development
KIRKLAND, Wash. /PRNewswire/ — Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the hiring of Gretchen Gary as Vice President of Global Therapy Development. …
New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients
KIRKLAND, Wash. — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three …
Cardiac Dimensions Carillon® System Improves FMR & Slows Worsening of Heart Failure
Study Conclusions Yesterday, Cardiac Dimensions met its primary endpoint. Results from the REDUCE FMR clinical study were published in the Journal of American College of Cardiology: Heart Failure. In this first blinded and sham-controlled randomized controlled trial of a percutaneous …
New Data Confirms Cardiac Dimensions’ Carillon® System Provides Acute Hemodynamic Efficacy in Patients with Functional Mitral Regurgitation
MANNHEIM, Germany – April 26, 2019 — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments to address functional mitral regurgitation (FMR) in patients with heart failure (HF), presented new data confirming significant reduction in regurgitant volume …
Cardiac Dimensions Appoints Carmelo Mastrandrea as Vice President of Sales
Medical Device Industry Expert to Spearhead European Sales of the Carillon Mitral Contour System KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment …
Cardiac Dimensions Announces DRG Reimbursement Code for Carillon® Mitral Contour System® in Germany
With Reimbursement in Place and Positive Late-Breaking Data, Company Expects Continued Growth in Germany Kirkland, Wash. – October 18, 2018 – Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related …
Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment
In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume KIRKLAND, Wash.- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular …
Cardiac Dimensions Announces the Randomization of its First Patient in the U.S. Pivotal Trial – The CARILLON Trial
KIRKLAND, Wash.- Cardiac Dimensions, Inc. a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the company has randomized its first patient in the CARILLON Pivotal Trial. The CARILLON Trial …
Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure
KIRKLAND, Wash.–(BUSINESS WIRE)– Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a $39 million Series B financing. The round includes new investor, Australia-based Hostplus, venture …
Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation
Kirkland, WA – Dec. 1, 2016 – Cardiac Dimensions, the leader in minimally invasive repair therapies for functional mitral regurgitation (FMR), today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the pivotal …
Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA
Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation First U.S. Randomized, Double-Blinded Study for this Underserved Patient Population Kirkland, WA – Dec. 1, 2016 …
Carillon Mitral Contour System Associated With Significant Improvement Of Functional Mitral Regurgitation
KIRKLAND, Wash. February 24, 2016 – A single-center study recently published in the Journal of Invasive Cardiology noted that treatment with Cardiac Dimensions’ Carillon® Mitral Contour System® resulted in significant improvement of functional (secondary) mitral regurgitation (FMR), a condition that …
Cardiac Dimensions Announces Appointment of Gregory D. Casciaro as President and Chief Executive Officer
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a medical device company dedicated to addressing functional mitral regurgitation using an innovative, minimally invasive approach, today announced the appointment of Gregory D. Casciaro as President and Chief Executive Officer (CEO), effective immediately. Mr. Casciaro will …
Cost-Utility Analysis Projects CARILLON Mitral Contour System as a Cost Effective Treatment Option for Functional Mitral Regurgitation
September 09, 2015 05:00 AM Eastern Daylight Time KIRKLAND, Wash.–(BUSINESS WIRE)–The CARILLON® Mitral Contour System® is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation …